- CRS Publications
- News
News
Authors:
Date:
PRNewswire: March 14, 2017 – SAN DIEGO, CA, U.S.A. – OncoSec Medical Incorporated (“OncoSec”) (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that they have entered into a technology access program (TAP) agreement with Inhibrx, LP, a privately…
Authors:
Date:
PRNewswire: March 14, 2017 – LUND, Sweden – Bonesupport AB, an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease, or related surgery, announces that it has extended the term of its U.S. distribution agreement with Zimmer…
Authors:
Date:
Business Wire: March 14, 2017 – BOSTON, MA, U.S.A., and MUMBAI, India – TA Associates, a leading global growth private equity firm, today announced it has completed an investment in Ideal Cures Private Limited, a supplier of ready-to-use coating products and excipients for tablets and capsules to…
Authors:
Date:
Business Wire: March 3, 2017 – SEATTLE, WA, U.S.A. – Impel NeuroPharma, a Seattle-based clinical-stage biotechnology company developing first-in-class intranasal drug treatments, announced today the appointment of Timothy S. Nelson as independent director of the board of directors.
Mr. Nelson has…
Authors:
Date:
PRNewswire: November 3, 2016 – SAN DIEGO, CA, U.S.A. – Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has accepted Genentech’s Biologics License Application for a subcutaneous formulation of rituximab in multiple blood cancer indications…
Authors:
Date:
PRNewswire: November 3, 2016 – WARRINGTON, PA, U.S.A. – Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, announced today that recently presented preclinical data at the 62nd Radiation Research…
